证券代码：002365 证券简称：永安药业 公告编号：2026-04 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易概述 潜江永安药业股份有限公司（以下简称"公司"或"甲方"）于 2026 年 1 月 6 日召开第七届董事会第十二次临时会议，审议通过了《关于与湖北永邦工程 技术有限公司签订<2026 年度设备加工及制造框架协议>暨关联交易的议案》， 同意公司及其子公司与湖北永邦工程技术有限公司（以下简称"湖北永邦"或"乙 方"）签署《2026 年度设备加工及制造框架协议》，委托湖北永邦提供满足公 司及其子公司技术质量指标等要求的加工及制造业务，具体包括设备制造安装、 机电设备及管道安装等其他相关工程的业务，交易总金额不超过 2,000 万元人民 币，协议自本次董事会批准之日起生效，协议有效期一年。关联董事陈勇先生、 陈子笛先生在本次董事会审议该项议案时回避表决，非关联董事以同意 5 票、反 对 0 票、弃权 0 票通过了该议案。 公司控股股东及实际控制人陈勇先生系湖北永邦的实际控制人，持有湖北永 邦 51%的股权，根据《深圳证券交易所股票上市规则 ...

潜江永安药业股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 证券代码：002365 证券简称：永安药业 公告编号：2026-05 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2026 年 01 月 22 日 14:30:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 01 月 22 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2026 年 01 月 22 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2026 年 ...

证券代码：002365 证券简称：永安药业 公告编号：2026-01 潜江永安药业股份有限公司 第七届董事会第十二次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）第七届董事会第十二次临 时会议的会议通知于 2025 年 12 月 30 日以书面、电话、传真、电子邮件等形式 送达公司全体董事，会议于 2026 年 1 月 6 日在公司会议室以通讯方式召开，本 次会议应参与审议表决董事 7 人，实际参与审议表决董事 7 人。本次会议由公 司董事长陈勇先生主持，会议的召集和召开符合《公司法》及《公司章程》的规 定。会议以书面记名投票方式进行逐项表决，通过了如下决议： 1、审议《关于吸收合并全资子公司湖北凌安科技有限公司的议案》 表决结果：同意 7 票，反对 0 票，弃权 0 票。 董事会同意对全资子公司湖北凌安科技有限公司（以下简称"凌安科技"） 进行吸收合并，合并完成后，凌安科技将予以注销，其全部资产、债权、债务、 业务、人员及其他一切权利与义务等由公司依法承继。 本议案尚需提交公司股东会审议。 具 ...

永安药业公告，公司拟对全资子公司湖北凌安科技有限公司进行吸收合并，合并完成后，凌安科技将予 以注销，其全部资产、债权、债务、业务、人员及其他一切权利与义务等由公司依法承继。凌安科技最 近一年及一期主要财务数据：2024年12月31日，资产总额1.8亿元，负债总额8371.19万元，净资产 9622.48万元；2025年1-9月营业收入7047.11万元，净利润-1115.43万元。 ...

证券日报网讯 1月5日，永安药业在互动平台回答投资者提问时表示，截至2025年12月10日，公司股东 人数为51743户。 （文章来源：证券日报） ...

证券日报网讯1月5日，永安药业（002365）在互动平台回答投资者提问时表示，截至2025年12月19日， 公司股东人数为50868户。 ...

Group 1 - The core viewpoint of the news is that Yong'an Pharmaceutical has experienced significant stock price fluctuations and changes in financial performance, with a notable increase in stock price year-to-date but a decline in recent trading periods [1][2]. Group 2 - As of December 18, Yong'an Pharmaceutical's stock price increased by 2.01% to 15.25 CNY per share, with a market capitalization of 4.494 billion CNY [1]. - The company has seen a year-to-date stock price increase of 93.23%, but it has declined by 0.20% over the last five trading days, 7.41% over the last 20 days, and 15.79% over the last 60 days [1]. - Yong'an Pharmaceutical has appeared on the trading leaderboard 30 times this year, with the most recent appearance on July 21, where it recorded a net buy of -289 million CNY [1]. Group 3 - For the period from January to September 2025, Yong'an Pharmaceutical reported operating revenue of 577 million CNY, a year-on-year decrease of 6.72%, and a net profit attributable to shareholders of 25.4963 million CNY, down 58.78% year-on-year [2]. - The company has distributed a total of 401 million CNY in dividends since its A-share listing, with 87.6649 million CNY distributed over the past three years [3]. Group 4 - Yong'an Pharmaceutical is primarily engaged in the research, production, and sales of taurine products, with taurine accounting for 64.14% of its main business revenue [1]. - The company is classified under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and raw materials, and is associated with various concept sectors including pet economy, pharmaceutical e-commerce, and graphene [1].

Core Viewpoint - Yong'an Pharmaceutical (002365) clarified that its main product, taurine, is used as a food additive primarily in the food and beverage industry, and that its subsidiary, Yong'an Health, offers products suitable for fatigue relief. The company and its subsidiaries do not supply related products directly to the military [1]. Group 1 - The main product of the company is taurine, which serves as a food additive [1] - Taurine is primarily applied in the food and beverage industry [1] - Yong'an Health, a subsidiary, has products aimed at individuals seeking fatigue relief [1] Group 2 - The company and its subsidiaries have not supplied related products to the military [1]

Core Viewpoint - The company, Yong'an Pharmaceutical (002365.SZ), has clarified that it does not currently develop or produce the drug Liraglutide, which has been inquired about for its potential use in weight loss and diabetes treatment [2][4]. Group 1: Company Operations - Yong'an Pharmaceutical primarily engages in three business areas: research, production, and sales of taurine products; research, production, and sales of health foods; and research, production, and sales of special dietary foods (creatine) [2][4]. - The company has not developed or produced Liraglutide products as of the latest update [2][4].

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) is primarily engaged in three business segments: the research, production, and sales of taurine products; the research, production, and sales of health foods; and the research, production, and sales of special dietary foods (creatine) [1] Business Segments - The company focuses on the development, production, and sales of taurine products [1] - The company also engages in the research, production, and sales of health foods [1] - Additionally, the company is involved in the research, production, and sales of special dietary foods, specifically creatine [1] - Currently, the company has not commenced the production or research of limonamide products [1]